Clinical Trial Update: FT516 and IL2 With Enoblituzumab for Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for FT516 and IL-2 with enoblituzumab in ovarian cancer-related conditions, completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Adenocarcinoma
• Ovarian Cancer
• Peritoneal Cavity Cancer

Drugs mentioned

• Enoblituzumab (enoblituzumab)
• FT516
• IL-2 (Interleukin-2)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Ovarian Cancer, Fallopian Tube Adenocarcinoma | Phase 1 | Status: COMPLETED | Results posted: 2023-04-03